Infliximab treatment for steroid-refractory acute graft-versus-host disease

Haematologica

Volumn 89, Issue 11, 2004, Pages 1352-1359

  Patriarca, Francesca ^a   Sperotto, Alessandra ^a   Damiani, Daniela ^a   Morreale, Giuseppe ^b   Bonifazi, Francesca ^c   Olivieri, Attilio ^d   Ciceri, Fabio ^e   Milone, Giuseppe ^f   Cesaro, Simone ^g   Bandini, Giuseppe ^c   Dini, Giorgio ^b   Corradini, Paolo ^h   Fanin, Renato ^a  

^a UNIVERSITY OF UDINE   (Italy)

^b G GASLINI INSTITUTE   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^e SAN RAFFAELE HOSPITAL   (Italy)

^f UNIVERSITY OF CATANIA   (Italy)

^g UNIVERSITY OF PADOVA   (Italy)

^h UNIVERSITY OF MILAN   (Italy)

Author keywords

Acute GVHD; Infliximab; TNF

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOPHOSPHAMIDE A; INFLIXIMAB; MEPREDNISONE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGE; ARTICLE; BACTERIAL PNEUMONIA; CANDIDIASIS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG RESPONSE; ENCEPHALITIS; ENTERITIS; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN TISSUE; LUNG ASPERGILLOSIS; MALE; RETROSPECTIVE STUDY; SEPTIC SHOCK; SEPTICEMIA; SURVIVAL RATE;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STEROIDS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 9144253168     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Hill GR, Ferrara JLM. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 2000; 95:2754-9.
2. Stark GL, Richardson AC, Graham JH, Dickinson MA, Middletom GP. Plasma levels of soluble tumor necrosis factor receptor type II correlate with subsequent GVHD development in the sibling allograft setting. Blood 2003; 5346a[abstract].
3. Kayaba H, Hirokawa M, Watanabe A, Saitoth N, Changhao C, Yamada Y, et al. Serum markers of graft-versus-host disease after bone marrow transplantation. J Allerg Clin Immunol 2000;106:1-9.
4. Sakata N, Yasui M, Okamura T, Inoue M, Yumura-Yagi K, Kawa K. Kinetics of plasma cytokines after haematopoietic stem cell transplantation from unrelated donors: the ratio of plasma IL-10/sTNFR level as a potential prognostic marker in severe acute graft-versus-host disease. Bone Marrow Transplant 2001;27:1153-61.
5. Kobbe J, Schneider P, Rohr U, Fenk R, Neumann F, Aivado M, et al. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse anti TNF-á antibody. Bone Marrow Transplant 2001; 28: 47-9.
6. Couriel D, Hicks K, Ipolitti C, de Lima M, Donato M, Martin T, et al. Infliximab for the treatment of graft-versus-host disease in allogeneic transplant recipients: an update. Blood 2000; 96:1724a [abstract].
7. Herve P, Flesh M, Tiberrghien P, Wijdenes J, Racadot E, Bordigoni, et al. Phase I-II trial of a monoclonal anti-tumor necrosis factor a antibody for the treatment of refractory severe acute graft-versus-host disease Blood 1992; 79: 3362-8.
8. Couriel D, Saliba R, Hicks K, Cohen A, Ippolity C, Neumann J, et al. TNF-α inhibition for the treatment of chronic GVHD Blood 2002;100:3343a[abstract].
9. Browning MB, Kugathasan S, Casper JT, Margolis DA. Infliximab for chronic GVHD in pediatric patients. Blood 2002;100:3345a[abstract].
10. Trenschel R, Ditschkowski M, Biersack H, Trampenau C, Steckel NK, Peceny H, et al. Infliximab as treatment for steroid refractory acute and chronic graft-versus-host disease. Blood 2002;100:5372a [abstract].
11. Jacobsohn DA, Hallick J, Anders V, McMillan S, Morris L, Vogelsang GB. Infliximab for steroid-refractory acute GVHD: a case series. Am J Haematol 2003;74:119-24.
12. Couriel D, Saliba R, Hicks K, Ippoliti C, de Lima M, Hosing C, et al. Tumor necrosis factor a blockade for the treatment of acute GVHD. Blood 2004;104:649-54.
13. Scallon BJ, Moore MA, Trinh H, Knight DH, Ghnayeb J. Chimeric anti-TNFα monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions. Cytokine 1995; 7:1280-9.
14. Tamada K, Tamura H, Flies D, Fu YX, Celes E, Pease LR, et al. Blockade of LIGHT/LTb and CD40 signaling induces allospecific T anergy, preventing graft-versus-host disease. J Clin Invest 2002;109:549-57.
15. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974;18:295-304.
16. Shulman HM, Sullivan KM, Weiden PL, Mc Donald GB, Striker GE, Sale GE, et al. Chronic graft-versus host syndrome in man: a long term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69:204-17.
17. Andolina M, Rabusin M, Maximova N, Di Leo G. Etanercept in graft-versus-host-disease. Bone Marrow Transplant 2000; 26:929.
18. Campos A, Vaz PC, Costa N, Mendes J, Roncon S, Barbosa I, et al. Infliximab as salvage therapy for patients with acute graft-versus-host disease refractory to steroids. Blood 2003; 102:5528a [abstract].
19. Yanik GA, Uberti JP, Ferrara JLM, White ES, Hellerstedt BA, Standford TJ, et al. Etanercept for sub-acute injury following allogeneic stem cell transplantation. Blood 2003, 102: 1718a[abstract].
20. Uberti JP, Ayash L, Levine JS, Samuel S, Reddy P, Becker M, et al. Phase I/II trial for the use of etanercept (Embrel) and solumedrol as primary treatment for acute graft-versus-host disease (a GVHD). Blood 2003, 102:854a[abstract].
21. Min CK, Lee WY, Min DJ, Lee DG, Kim YJ, Park YH, et al. The kinetics of circulating cytokines including IL-6, TNF-α, IL-8 and IL-10 following allogeneic stem cell transplantation. Bone Marrow Transplant 2001;28:935-40.
22. Ferrȧ C, de Sanjosè S, Gallardo D, Berlanga JJ, Rueda F, Marin D, et al. IL-6 and IL-8 levels in plasma during haematopoietic progenitor transplantation. Haematologica 1998;83:1082-7.
23. Holler E, Kolb HJ, Kaul M, Ledderose G, Duell T, Seeber B, et al. Modulation of acute graft-versus-host disease after allogeneic bone marrow transplantation by tumour necrosis factor α (TNF-α) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF-a (MAK 195F). Blood 1995;86:890-9.
24. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, tumour necrosis factor α-neutralizing agent. N Engl J Med 2001; 345:1098-104.
25. Lee JH, Slifman NR, Gershon SK, Edwards ET, Braun MM. Life-threatening histoplasmosis complicating immunotherapy with tumour necrosis factor α antagonist infliximab and etanercept. Arthritis Rheum 2002; 46:2565-70.
26. Marty FM, Lee SJ, Fahey MM, Alyea EP, Soiffer RJ, Antin JH, Baden LR. Infliximab use in severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic haematopoietic stem cell transplant recipients: a cohort study. Blood 2003;102:2776-86.